05:41:17 Europe / Stockholm

Bifogade filer

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande


Calmark Sweden är verksamma inom medicinteknik. Bolaget specialiserar sig inom utveckling av diagnostiska verktyg riktade mot nyfödda barn. Tekniken utgår ifrån den egenutvecklade plattformen och används för analys de första veckorna efter födseln. Instrumentet används som biomarkör för att studera blodvärden. Störst verksamhet återfinns inom den nordiska marknaden. Bolaget grundades under 2007 och har sitt huvudkontor i Karlstad.


2022-02-25 Bokslutskommuniké 2021
2021-11-26 Kvartalsrapport 2021-Q3
2021-08-27 Kvartalsrapport 2021-Q2
2021-05-28 Kvartalsrapport 2021-Q1
2021-05-19 Ordinarie utdelning CALMA B 0.00 SEK
2021-05-18 Årsstämma 2021
2021-02-26 Bokslutskommuniké 2020
2020-12-23 Extra Bolagsstämma 2020
2020-11-25 Kvartalsrapport 2020-Q3
2020-08-27 Kvartalsrapport 2020-Q2
2020-05-20 Kvartalsrapport 2020-Q1
2020-05-15 Ordinarie utdelning CALMA B 0.00 SEK
2020-05-14 Årsstämma 2020
2020-02-28 Bokslutskommuniké 2019
2019-11-25 Kvartalsrapport 2019-Q3
2019-11-06 Extra Bolagsstämma 2019
2019-08-27 Kvartalsrapport 2019-Q2
2019-05-23 Kvartalsrapport 2019-Q1
2019-05-10 Ordinarie utdelning CALMA B 0.00 SEK
2019-05-09 Årsstämma 2019
2019-02-28 Bokslutskommuniké 2018
2018-11-26 Kvartalsrapport 2018-Q3
2018-08-27 Kvartalsrapport 2018-Q2
2020-09-01 17:09:53

Calmark Sweden AB announces today that the product development of an LDH test for assessment (triage) of COVID-19 is proceeding according to plan; the test is now projected to obtain CE conformity marking in Q1 2021. The project has now successfully completed the chemical impregnation in Calmark's recently installed BioDot machine, which will be used in the production line. 

CE conformity marking and the development of medical technology products follows a seven-step process, where the first three steps involve identification of requirements specification and development to cover them. The product is then verified against the prescribed requirements and validated by potential end users (steps four and five). The development project is then closed, and design transfer to production is done in step six. In the final and seventh step, the product formally obtains its CE mark approval.

Tests for LDH in adults, which have been diagnosed with Covid-19, will be a part of the assessment of the development of the disease course. Studies indicate that the occurrence of increased levels of LDH in early onset of Covid-19 improves the possibilities of identifying patients at risk, assess severity and start the clinical intervention and monitoring. Doing that the prognosis improves and the possibility of recovery increases for the patients. Thus, LDH is an important biomarker for fast triage of patients with Covid-19.

"It is good to see that the project is moving forward," says Anna Söderlund, CEO of Calmark. "The installation of our BioDot machine was a great stride forward and we can now see that the recipe for our LDH chemistry is working well in a large-scale production environment."


This information is information that Calmark Sweden AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, on 1 September 2020, 17:05 CEST.

Every care has been taken in the translation of this document. In the event of discrepancies, the Swedish original will supersede the English translation.